Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 17, Issue 4, Pages 261-279Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrd.2017.243
Keywords
-
Funding
- National Institute of Allergy and Infectious Disease (NIAID) of the US National Institutes of Health (NIH) [CHAVI-ID UM1-AI100645, R01-AI050484, R01-AI124429, R01-AI084860]
- Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) [OPP1033102]
- Defense Advanced Research Projects Agency [HR0011-17-2-0069]
- New Frontier Sciences division of Takeda Pharmaceuticals
- Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) [UM1-AI100645]
- Gates Foundation [OPP1066832]
- Bill and Melinda Gates Foundation [OPP1066832] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available